TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer - Nature

TROP2 marks poor-prognosis colorectal cancer cells with fetal-like, therapy-resistant states, and therapeutic targeting of TROP2 with antibody–drug conjugates in combination with chemotherapy enhances treatment efficacy by modulating tumour cell plasticity and overcoming resistance.

Raccontata danature.com